BEONE MEDICINES USA, INC. (FKA BEIGENE USA, INC.)

View full entity profile (contributions, contracts, SEC) →

Lobbying Spend

—

Filings

Firms Hired

Active Period

2020–2026

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2026	—	3	1
2025	—	4	1
2024	—	4	1
2023	—	4	1
2022	—	7	1
2021	—	8	1
2020	—	3	1

Hired Firms

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
TIBER CREEK GROUP	—	33

Government Bodies Lobbied

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
HOUSE OF REPRESENTATIVES	32
SENATE	32
Commerce, Dept of (DOC)	9
Treasury, Dept of	2
Health & Human Services, Dept of (HHS)	1

Top Issues

Most frequently reported lobbying issues

Issue Code	Description	Reports
Health Issues	Health Issues	33
Medicare/Medicaid	Medicare/Medicaid	30
Trade (domestic/foreign)	Trade (domestic/foreign)	15
Manufacturing	Manufacturing	10
Budget/Appropriations	Budget/Appropriations	3

Bills Explicitly Cited (25)

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

H.R. 946119th Congress

ORPHAN Cures Act

2026 · first_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act; Issues related to the One Big Beautiful Bill Act (PL 119-21).

Client expense: — · Firm income: $70,000

Matched citations: H.R. 946

S. 1862119th Congress

ORPHAN Cures Act

2026 · first_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act; Issues related to the One Big Beautiful Bill Act (PL 119-21).

Client expense: — · Firm income: $70,000

Matched citations: S. 1862

H.R. 946119th Congress

ORPHAN Cures Act

2025 · fourth_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act; Issues related to the One Big Beautiful Bill Act (PL 119-21).

Client expense: — · Firm income: $70,000

Matched citations: H.R. 946

S. 1862119th Congress

ORPHAN Cures Act

2025 · fourth_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act; Issues related to the One Big Beautiful Bill Act (PL 119-21).

Client expense: — · Firm income: $70,000

Matched citations: S. 1862

Show 21 more cited filings

H.R. 946119th Congress

ORPHAN Cures Act

2025 · third_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act; Issues related to the One Big Beautiful Bill Act (PL 119-21).

Client expense: — · Firm income: $70,000

Matched citations: H.R. 946

S. 1862119th Congress

ORPHAN Cures Act

2025 · third_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act; Issues related to the One Big Beautiful Bill Act (PL 119-21).

Client expense: — · Firm income: $70,000

Matched citations: S. 1862

H.R. 946119th Congress

ORPHAN Cures Act

2025 · second_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act; Issues related to the One Big Beautiful Bill Act (PL 119-21).

Client expense: — · Firm income: $70,000

Matched citations: H.R. 946

S. 1862119th Congress

ORPHAN Cures Act

2025 · second_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act; Issues related to the One Big Beautiful Bill Act (PL 119-21).

Client expense: — · Firm income: $70,000

Matched citations: S. 1862

H.R. 946119th Congress

ORPHAN Cures Act

2025 · first_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to H.R. 946 - ORPHAN Cures Act.

Client expense: — · Firm income: $70,000

Matched citations: H.R. 946

H.R. 5376117th Congress

Inflation Reduction Act of 2022

2022 · third_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to drug pricing and reimbursement for prescription drugs related to H.R. 5376 - Build Back Better Act, Subtitle J (Part B and D drug pricing); Issues related to Prescription Drug User Fee Reauthorization; Issues related to clinical trials. H.R. 6833 Affordable Insulin Now Act (Continuing Resolution Shell); H.R. 7667 - Food and Drug Amendments of 2022; S. 4348 - FDA Safety and Landmark Advancements (FDASLA) Act.H.R.5376 - Inflation Reduction Act of 2022 - Public Law No: 117-169.

Client expense: — · Firm income: $60,000

Matched citations: H.R. 5376, H.R.5376

H.R. 5376117th Congress

Inflation Reduction Act of 2022

2022 · third_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to drug pricing and reimbursement for prescription drugs related to H.R. 5376 - Build Back Better Act, Subtitle J (Part B and D drug pricing). H.R.5376 - Inflation Reduction Act of 2022 - Public Law No: 117-169.

Client expense: — · Firm income: $60,000

Matched citations: H.R. 5376, H.R.5376

H.R. 6833117th Congress

Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023

2022 · third_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to drug pricing and reimbursement for prescription drugs related to H.R. 5376 - Build Back Better Act, Subtitle J (Part B and D drug pricing); Issues related to Prescription Drug User Fee Reauthorization; Issues related to clinical trials. H.R. 6833 Affordable Insulin Now Act (Continuing Resolution Shell); H.R. 7667 - Food and Drug Amendments of 2022; S. 4348 - FDA Safety and Landmark Advancements (FDASLA) Act.H.R.5376 - Inflation Reduction Act of 2022 - Public Law No: 117-169.

Client expense: — · Firm income: $60,000

Matched citations: H.R. 6833

H.R. 7667117th Congress

Food and Drug Amendments of 2022

2022 · third_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to drug pricing and reimbursement for prescription drugs related to H.R. 5376 - Build Back Better Act, Subtitle J (Part B and D drug pricing); Issues related to Prescription Drug User Fee Reauthorization; Issues related to clinical trials. H.R. 6833 Affordable Insulin Now Act (Continuing Resolution Shell); H.R. 7667 - Food and Drug Amendments of 2022; S. 4348 - FDA Safety and Landmark Advancements (FDASLA) Act.H.R.5376 - Inflation Reduction Act of 2022 - Public Law No: 117-169.

Client expense: — · Firm income: $60,000

Matched citations: H.R. 7667

S. 4348117th Congress

FDASLA Act of 2022

2022 · third_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to drug pricing and reimbursement for prescription drugs related to H.R. 5376 - Build Back Better Act, Subtitle J (Part B and D drug pricing); Issues related to Prescription Drug User Fee Reauthorization; Issues related to clinical trials. H.R. 6833 Affordable Insulin Now Act (Continuing Resolution Shell); H.R. 7667 - Food and Drug Amendments of 2022; S. 4348 - FDA Safety and Landmark Advancements (FDASLA) Act.H.R.5376 - Inflation Reduction Act of 2022 - Public Law No: 117-169.

Client expense: — · Firm income: $60,000

Matched citations: S. 4348

H.R. 5376117th Congress

Inflation Reduction Act of 2022

2022 · second_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to drug pricing and reimbursement for prescription drugs related to H.R. 5376 - Build Back Better Act, Subtitle J (Part B and D drug pricing).

Client expense: — · Firm income: $60,000

Matched citations: H.R. 5376

H.R. 5376117th Congress

Inflation Reduction Act of 2022

2022 · second_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to drug pricing and reimbursement for prescription drugs related to H.R. 5376 - Build Back Better Act, Subtitle J (Part B and D drug pricing); Issues related to Prescription Drug User Fee Reauthorization; Issues related to clinical trials.

Client expense: — · Firm income: $60,000

Matched citations: H.R. 5376

H.R. 5376117th Congress

Inflation Reduction Act of 2022

2022 · first_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to drug pricing and reimbursement for prescription drugs related to H.R. 5376 - Build Back Better Act, Subtitle J (Part B and D drug pricing); Issues related to Prescription Drug User Fee Reauthorization.

Client expense: — · Firm income: $60,000

Matched citations: H.R. 5376

H.R. 5376117th Congress

Inflation Reduction Act of 2022

2022 · first_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to drug pricing and reimbursement for prescription drugs related to H.R. 5376 - Build Back Better Act, Subtitle J (Part B and D drug pricing).

Client expense: — · Firm income: $60,000

Matched citations: H.R. 5376

H.R. 5376117th Congress

Inflation Reduction Act of 2022

2022 · third_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to drug pricing and reimbursement for prescription drugs related to H.R. 5376 - Build Back Better Act, Subtitle J (Part B and D drug pricing); Issues related to Prescription Drug User Fee Reauthorization; Issues related to clinical trials. H.R. 6833 Affordable Insulin Now Act (Continuing Resolution Shell); H.R. 7667 - Food and Drug Amendments of 2022; S. 4348 - FDA Safety and Landmark Advancements (FDASLA) Act.H.R.5376 - Inflation Reduction Act of 2022 - Public Law No: 117-169.

Client expense: — · Firm income: $60,000

Matched citations: H.R. 5376, H.R.5376

H.R. 5376117th Congress

Inflation Reduction Act of 2022

2022 · third_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to drug pricing and reimbursement for prescription drugs related to H.R. 5376 - Build Back Better Act, Subtitle J (Part B and D drug pricing). H.R.5376 - Inflation Reduction Act of 2022 - Public Law No: 117-169.

Client expense: — · Firm income: $60,000

Matched citations: H.R. 5376, H.R.5376

H.R. 6833117th Congress

Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023

2022 · third_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to drug pricing and reimbursement for prescription drugs related to H.R. 5376 - Build Back Better Act, Subtitle J (Part B and D drug pricing); Issues related to Prescription Drug User Fee Reauthorization; Issues related to clinical trials. H.R. 6833 Affordable Insulin Now Act (Continuing Resolution Shell); H.R. 7667 - Food and Drug Amendments of 2022; S. 4348 - FDA Safety and Landmark Advancements (FDASLA) Act.H.R.5376 - Inflation Reduction Act of 2022 - Public Law No: 117-169.

Client expense: — · Firm income: $60,000

Matched citations: H.R. 6833

H.R. 7667117th Congress

Food and Drug Amendments of 2022

2022 · third_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to drug pricing and reimbursement for prescription drugs related to H.R. 5376 - Build Back Better Act, Subtitle J (Part B and D drug pricing); Issues related to Prescription Drug User Fee Reauthorization; Issues related to clinical trials. H.R. 6833 Affordable Insulin Now Act (Continuing Resolution Shell); H.R. 7667 - Food and Drug Amendments of 2022; S. 4348 - FDA Safety and Landmark Advancements (FDASLA) Act.H.R.5376 - Inflation Reduction Act of 2022 - Public Law No: 117-169.

Client expense: — · Firm income: $60,000

Matched citations: H.R. 7667

S. 4348117th Congress

FDASLA Act of 2022

2022 · third_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to drug pricing and reimbursement for prescription drugs related to H.R. 5376 - Build Back Better Act, Subtitle J (Part B and D drug pricing); Issues related to Prescription Drug User Fee Reauthorization; Issues related to clinical trials. H.R. 6833 Affordable Insulin Now Act (Continuing Resolution Shell); H.R. 7667 - Food and Drug Amendments of 2022; S. 4348 - FDA Safety and Landmark Advancements (FDASLA) Act.H.R.5376 - Inflation Reduction Act of 2022 - Public Law No: 117-169.

Client expense: — · Firm income: $60,000

Matched citations: S. 4348

H.R. 5376117th Congress

Inflation Reduction Act of 2022

2022 · second_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to drug pricing and reimbursement for prescription drugs related to H.R. 5376 - Build Back Better Act, Subtitle J (Part B and D drug pricing); Issues related to Prescription Drug User Fee Reauthorization; Issues related to clinical trials.

Client expense: — · Firm income: $60,000

Matched citations: H.R. 5376

H.R. 5376117th Congress

Inflation Reduction Act of 2022

2022 · second_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to drug pricing and reimbursement for prescription drugs related to H.R. 5376 - Build Back Better Act, Subtitle J (Part B and D drug pricing).

Client expense: — · Firm income: $60,000

Matched citations: H.R. 5376

Source: Senate LDA

BEONE MEDICINES USA, INC. (FKA BEIGENE USA, INC.) — Lobbying Disclosure | Poliscope